Unusual 11 Mid-Day Movers 6/8: ANPI, MFRI, RSOL, KERX Higher; XTNT, EMIS, AGEN, AIB Lower

June 8, 2009 1:19 PM EDT

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) 40% HIGHER; announced that the U.S. FDA has granted 510(k) clearance for the Option(TM) Inferior Vena Cava Filter in the United States, for use in both permanent and retrievable indications. Click here for the full report.

MFRI, Inc. (NASDAQ: MFRI) 28.3% HIGHER; reports Q1 EPS of $0.88, compared to $0.06 in the same quarter last year. Revenue for the quarter was $68 million, versus $66 million in Q108.

XTENT (Nasdaq: XTNT) 25.6% LOWER; correcting today following last week's 500%+ surge on news that it received conditional approval from the US FDA for an Investigational Device Exemption authorizing it to begin its pivotal clinical program, composed of two pivotal trials called CUSTOM IV and CUSTOM IV Angio to support the approval in the United States of its Custom NX(R) Drug Eluting Stent System.

Real Goods Solar (Nasdaq: RSOL) 22.8% HIGHER; continuing higher this week following Friday's 55% surge on the back of news that the company will install a $30 million solar program for the Fremont Union High School District.

Emisphere Technologies, Inc. (NASDAQ: EMIS) 21.8% LOWER; today announced that it received notification from the NASDAQ Stock Market that its shares will be delisted from the NASDAQ Capital Market effective with the open of business on Tuesday, June 9, 2009.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 20.4% HIGHER; announced positive results of the Phase 2 study of Zerenex for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on thrice weekly hemodialysis. Here is more color.

Micromet, Inc. (Nasdaq: MITI) 19.9% HIGHER; last week presented an update from an ongoing clinical study of the BiTE(R) antibody blinatumomab (MT103) for non-Hodgkin's lymphoma at the 14th Congress of the European Hematology Association, held June 4 to 7 in Berlin, Germany. Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells. Click here for the full report.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) 16.2% HIGHER; announced a late-breaking poster presentation of positive results from BLOOM, the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management, at the American Diabetes Association's 69th Scientific Sessions. Lorcaserin patients achieved highly significant categorical and absolute weight loss in Year 1, and continued treatment with lorcaserin in Year 2 helped significantly more patients maintain their weight loss as compared to those on placebo. Treatment with lorcaserin also resulted in highly significant improvements as compared to placebo in multiple secondary endpoints associated with cardiovascular risk. Lorcaserin did not result in increased risk of depression and was not associated with the development of cardiac valvular insufficiency.

Antigenics (Nasdaq: AGEN) 16.1% LOWER; correcting once again this week following a more than 200% rise last week on the back of positive data on Oncophage(R) at ASCO.

Allied Irish Banks (NYSE: AIB) 14.7% LOWER; tumbling today as S&P lowered its sovereign credit rating on Ireland from AA+ to AA.

Palm (Nasdaq: PALM) 10% LOWER; shares are sinking today following the launch of its Pre device on Saturday.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

Related Categories

Special Reports

Stocks Mentioned

Related Entities

• Standard & Poor's
• Unusual 11 Mid-Day Movers

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?